Anogen-Yes Biotech

10/28/2026

Tiziana Life Sciences recently reported positive preclinical findings for intranasal foralumab, a fully human anti-CD3 monoclonal antibody being developed to modulate neuroinflammation.

In an aging model, nasal anti-CD3 was associated with:

• Reduced microglial activation and chronic neuroinflammation
• Increased neurogenesis in the hippocampus, a key region for learning and memory
• Reduced cellular senescence and age-related inflammatory markers
• Improved cognitive performance

Foralumab is designed to stimulate regulatory T cells, which may help regulate inflammatory activity in the central nervous system. This non-invasive intranasal approach is also being explored across several neuroinflammatory and neurodegenerative conditions.

While these aging results are still preclinical, they highlight an interesting direction in neuroscience: targeting the immune system and neuroinflammation as part of strategies to preserve brain function during aging.

https://www.tizianalifesciences.com/tiziana-announces-data-showing-nasal-anti-cd3-improves-cognition-associated-with-aging/

Data highlights nasal anti-CD3’s potential as a novel approach to address neuroinflammation associated with aging, which contributes to cognitive decline in age-related disorders. In the study, nasal anti-CD3 reversed key aspects of brain aging, and improved cognition.

10/21/2026

Recent 2026 updates are reinforcing tau as one of the most closely watched therapeutic targets in Alzheimer’s disease — but the field is moving beyond traditional anti-tau antibodies alone.

At AAIC 2026, Biogen reported that diranersen (BIIB080), an antisense oligonucleotide targeting MAPT mRNA, produced robust reductions in tau pathology in its Phase 2 CELIA study. At the 60 mg dose, Biogen reported slowing of decline across several cognitive measures, while CSF total tau fell by approximately 50–65%. The program is now moving toward Phase 3 development. Biogen

Meanwhile, Eisai’s etalanetug (E2814) is targeting the microtubule-binding region of tau. At AAIC 2026, Eisai reported reductions in the tau-tangle-associated biomarker eMTBR-tau243, including a 62% reduction in CSF at three months and 89% at nine months in a dominantly inherited AD study. Etalanetug is also being studied in combination with lecanemab, highlighting growing interest in targeting both amyloid and tau together. Eisai Media Center

Other approaches continue to broaden the field. BMS-986446 is being evaluated in the Phase 2 TargetTau-1 study as an anti-MTBR-tau antibody, while JNJ-2056 is using active immunotherapy to stimulate the body’s own immune response against pathological tau. Bristol Myers Squibb

Another major challenge is delivery. Denali’s DNL628 (OTV:MAPT) uses an Oligonucleotide TransportVehicle designed to cross the blood-brain barrier and suppress tau production by targeting MAPT. The first patients entered Phase 1b in 2026, with initial biomarker data expected in 2027. Denali Therapeutics

Together, these programs suggest that Alzheimer’s research is moving toward a more diversified strategy: gene silencing, targeted antibodies, active immunotherapy, combination treatment, and improved CNS delivery.

The next question may no longer be simply amyloid or tau? — but rather how multiple disease mechanisms can be targeted together at the right stage of Alzheimer’s disease.

https://media-us.eisai.com/2026-07-13-Eisai-Presents-Latest-Findings-Showed-Etalanetug-Reduced-Alzheimers-Disease-Tau-Tangle-Specific-Plasma-Biomarker-MTBR-tau243-at-Alzheimers-Association-International-Conference-R-AAIC-R-2026

Eisai presents findings at AAIC 2026 assessing the effect of the anti-MTBR tau antibody etalanetug on the tau-tangle plasma biomarker MTBR-tau243.

10/14/2026

Here’s a polished LinkedIn-style post based on current 2026 anti-tau developments:
Anti-Tau Therapies Are Entering a New Era in Alzheimer’s Research
Recent 2026 updates are reinforcing tau as one of the most important therapeutic targets in Alzheimer’s disease, with development moving beyond traditional antibodies toward a broader mix of gene-silencing, anti-MTBR antibodies, combination therapy, and gene therapy.
At AAIC 2026, Biogen reported that diranersen (BIIB080), an antisense oligonucleotide targeting MAPT mRNA, produced robust reductions in CSF tau and brain tau pathology in the Phase 2 CELIA study, together with signals of slowed clinical decline. Biogen plans to advance the program into Phase 3 development. Biogen
Meanwhile, etalanetug (E2814) is targeting the microtubule-binding region of tau. Eisai reported substantial reductions in the tau-tangle biomarker eMTBR-tau243, and the antibody is being studied both in dominantly inherited Alzheimer’s disease and in combination with lecanemab in early sporadic disease. Eisai Media Center
Other approaches are also expanding the field. BMS-986446 is in Phase 2 development as another anti-MTBR-tau antibody and has received FDA Fast Track designation, while Voyager’s VY1706 is taking a gene-therapy approach designed to reduce intracellular and extracellular tau after a single IV dose. Bristol Myers Squibb News
Together, these programs point toward a more diversified future for Alzheimer’s treatment—one where tau may be targeted through multiple mechanisms and potentially combined with anti-amyloid therapies to address different stages of disease biology.

🔗 Learn more: https://investors.biogen.com/node/30826

10/07/2026

A 2026 review published in Antibodies highlights that anti-TNF-α monoclonal antibodies used in inflammatory bowel disease (IBD) may work through multiple mechanisms beyond simply neutralizing soluble TNF-α.

In Crohn’s disease and ulcerative colitis, anti-TNF-α antibodies such as infliximab, adalimumab, and golimumab can bind both soluble TNF-α and membrane-bound TNF-α. This interaction may contribute to several additional immunoregulatory effects, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, apoptosis of membrane TNF-α–expressing cells, apoptosis of lamina propria T cells, and induction of regulatory T cells and macrophages.

The review also discusses why these broader mechanisms may help explain the established efficacy of anti-TNF therapies in IBD and why membrane-bound TNF-α remains an important area of research. Emerging approaches, including next-generation and dual-target inhibitors, may further expand how TNF-related pathways are targeted in inflammatory disease.

As biologic options continue to grow, understanding the distinct mechanisms behind each therapeutic class may help support more precise treatment selection and future antibody development.

Read the full article: https://pmc.ncbi.nlm.nih.gov/articles/PMC13509712/?utm_source=chatgpt.com

Inflammatory bowel diseases (IBDs), chronic inflammatory disorders of the gastrointestinal tract, are classified into Crohn’s disease (CD) and ulcerative colitis (UC). Despite differing clinical manifestations, both CD and UC share a common ...

09/30/2026

A 2026 review in Antibody Therapeutics examines how monoclonal antibodies have transformed the treatment of Crohn’s disease by targeting specific inflammatory pathways. The review covers established therapies including anti-TNF-α agents such as infliximab and adalimumab, anti-integrin therapy such as vedolizumab, and cytokine-targeted therapies including ustekinumab and risankizumab. PubMed
Despite major advances, important challenges remain. The authors report primary non-response in approximately 20%–40% of patients and secondary loss of response in 13%–20% annually, alongside concerns related to immunogenicity, safety, treatment costs, and long-term effectiveness. PubMed
The review also highlights emerging therapeutic targets including IL-36, IL-17C, SMAD7, TL1A, complement components, and microbiome-related pathways. Future strategies may increasingly involve personalized treatment, therapeutic drug monitoring, advanced antibody engineering, and bi- or polyspecific antibodies designed to target multiple disease pathways simultaneously. PubMed
As our understanding of Crohn’s disease continues to evolve, monoclonal antibody research remains an important area for developing more precise and durable therapeutic approaches.

Read the full article on PubMed: https://pubmed.ncbi.nlm.nih.gov/41930211/

Crohn's disease (CD) is a chronic inflammatory bowel disease with increasing global prevalence, significantly impacting patients' quality of life and healthcare costs. The introduction of monoclonal antibodies has revolutionized CD management, offering targeted therapy against specific inflammatory....

09/23/2026

A recent review published in Frontiers in Pharmacology highlights the growing importance of the interleukin-17 (IL-17) signaling pathway in chronic inflammation, autoimmune disorders, and cancer. IL-17 plays an important role in host defense and immune regulation, but dysregulated IL-17 signaling has been associated with conditions such as psoriasis, systemic lupus erythematosus, periodontitis, and cancer.

Current therapeutic strategies include monoclonal antibodies targeting IL-17 or its receptors, which have shown strong clinical efficacy. However, challenges such as cost, tissue pe*******on, immunogenicity, and treatment-related adverse effects are driving interest in alternative approaches, including emerging small-molecule inhibitors targeting the IL-17 pathway.

As research continues to uncover the molecular mechanisms behind IL-17 signaling, the pathway remains an important area for the development of next-generation therapies for inflammatory and immune-mediated diseases.

🔗 Read the full review: https://pmc.ncbi.nlm.nih.gov/articles/PMC13448234/

Interleukin-17 (IL-17) is a key pro-inflammatory cytokine that plays an essential role in host defense and immune regulation. Dysregulated IL-17 expression and signaling are implicated in the pathogenesis of a broad range of chronic inflammatory and ...

09/16/2026

The global TNF-α inhibitors market is projected to grow from $43.83 billion in 2025 to $44.95 billion in 2026, with further growth expected to reach $50.58 billion by 2030.

Key drivers highlighted in the 2026 market report include:

• Growing use of biologic therapies in autoimmune disease management
• Increasing biosimilar pe*******on
• Rising prevalence of inflammatory bowel disease
• Expanding patient access programs
• Continued adoption of subcutaneous TNF inhibitor therapies

TNF-α inhibitors remain an important therapeutic class across conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis. The report also notes that North America was the largest regional market in 2025.

As biosimilars expand and biologic treatment strategies continue to evolve, TNF-α inhibition remains an important area of research and therapeutic development.

📖 Read more: https://www.researchandmarkets.com/reports/5733874/tnf-alpha-inhibitors-market-report?utm_source=chatgpt.com

The TNF Alpha Inhibitors Market, valued at USD 44.95B in 2026, is projected to reach USD 50.58B by 2030, growing at a 3% CAGR.

09/09/2026

The 2026 Alzheimer’s disease drug development pipeline reflects continued growth and increasing diversity in therapeutic approaches.

According to the latest annual pipeline review:

• 158 drugs are being evaluated across 192 clinical trials
• 73% of agents are disease-targeting therapies designed to prevent, delay, or slow disease progression
• 35% of drugs in development are repurposed agents
• Nearly 55,000 participants are needed to support currently active trials
• The biopharmaceutical industry sponsors 59% of all trials and 72% of Phase 3 trials

The therapeutic landscape is also becoming more diverse. While amyloid-targeting therapies remain important, researchers are increasingly exploring other pathways, including inflammation and immune dysfunction, tau, metabolism, synaptic function, and other mechanisms involved in Alzheimer’s disease progression.

This expanding pipeline highlights both the complexity of Alzheimer’s disease and the growing effort to develop therapies that address multiple biological pathways.

📖 Read the full article:
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70251?utm_source=chatgpt.com

09/02/2026

A recent review published in Antibodies explores the multiple mechanisms through which anti-TNF-α antibodies may help control inflammation in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.

While anti-TNF-α therapies are well known for neutralizing soluble TNF-α, the review highlights additional actions involving membrane-bound TNF-α, including:

• Complement-dependent cytotoxicity
• Antibody-dependent cellular cytotoxicity
• Apoptosis of membrane TNF-α–expressing cells
• Apoptosis of lamina propria T cells
• Induction of regulatory T cells and macrophages

These multifaceted mechanisms may help explain the effectiveness of anti-TNF-α antibodies such as infliximab, adalimumab, and golimumab in reducing IBD-associated inflammation.

Understanding how therapeutic antibodies act beyond simple cytokine neutralization continues to provide valuable insight into antibody-based therapies and inflammatory disease research.

📖 Read the full review:
https://www.mdpi.com/2073-4468/15/4/71

Inflammatory bowel diseases (IBDs), chronic inflammatory disorders of the gastrointestinal tract, are classified into Crohn’s disease (CD) and ulcerative colitis (UC). Despite differing clinical manifestations, both CD and UC share a common immunopathogenesis, involving excessive production of pro...

08/26/2026

Tiziana Life Sciences has reported PET imaging results from a third MSA patient treated with intranasal foralumab, showing reductions in neuroinflammatory activity in key brain regions affected by the disease.

The patient demonstrated:

• Up to 34% reduction in standardized uptake value (SUV)

• Up to 26% reduction in standardized uptake value ratio (SUVR)

Importantly, these findings were consistent with results previously observed in the first two MSA patients, providing further evidence of the potential biological activity of intranasal foralumab in reducing neuroinflammation.

MSA is a rare and progressive neurodegenerative disease with currently no approved disease-modifying treatments, making continued research in this area especially important.

Tiziana plans to evaluate additional patients to further validate these findings and better understand the potential of intranasal foralumab.

Read the full article: https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-reports-reduction-brain-inflammation-third-multiple